Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 May;7(3):253-8.
doi: 10.1007/s11910-007-0038-y.

Epstein-Barr Virus and Multiple Sclerosis

Affiliations
Review

Epstein-Barr Virus and Multiple Sclerosis

Jan D Lünemann et al. Curr Neurol Neurosci Rep. .

Abstract

Epstein-Barr virus (EBV) is one of the most common and successful human viruses, infecting more than 90% of the world's adult population. Despite its strong tumorigenic potential, most virus carriers remain healthy due to maintenance of a delicate balance between the host's immune system, which limits production of virus particles, and the virus, which persists for the duration of the host's life. New data show that this balance is altered on a subtle level in patients with multiple sclerosis (MS) and other autoimmune diseases who show enhanced as well as less restricted T-cell and antibody responses to EBV-encoded antigens. Such quantitatively and qualitatively distinct immune responses and the virus' unique ability to immortalize B cells as well as to continuously stimulate strong T-cell responses during persistent infection suggest a possible role for EBV in the initiation and progression of symptomatic autoimmunity. We hypothesize that EBV promotes both autoimmune B and T-cell responses. EBV gene products might stimulate cross-reactive autoimmune B cells directly or increase their survival after infection. In addition, autoimmune T cells could be maintained via molecular mimicry between autoantigens and EBV antigens, and via the Th1 polarizing cytokine milieu of protective antiviral T-cell immunity. A better understanding of how EBV and EBV-specific immune control mechanisms interfere with the evolution of autoimmunity may generate a rationale for novel EBV-targeting therapeutic strategies aimed at the prevention and more efficient treatment of autoimmune diseases.

Similar articles

See all similar articles

Cited by 14 articles

See all "Cited by" articles

References

    1. Neurology. 1989 Jun;39(6):825-9 - PubMed
    1. Immunity. 1998 Sep;9(3):405-11 - PubMed
    1. Nat Immunol. 2002 Oct;3(10):940-3 - PubMed
    1. Nat Neurosci. 2004 Oct;7(10):1088-95 - PubMed
    1. N Engl J Med. 2003 Oct 2;349(14):1324-32 - PubMed

Publication types

MeSH terms

Substances

Feedback